BMY — Bristol-Myers Squibb Co. | Value Investing Lab

Decision Matrix

Buffett

Graham

Sowell

Framework Convergence

5/14

Graham Score

6/14

Buffett Score

NEUTRAL

Sowell Score

INVESTIGATE

Combined Signal

Graham

SPEC.

P/E 22.4x GAAP, borderline

IV: $43–$77

Buffett

HOLD

7.25% projected return

IV: $47.15

Sowell

NEUTRAL

Artificial (Patents)

Govt distortions dominant

Reasoning Chain

How Each Framework Contributed

📐 Graham: At $60.74, there is NO margin of safety on any conservative basis. Prevents a BUY signal regardless of business quality. Entry price: below $54 for aggressive, below $42 for conservative.

🎯 Buffett: BMY's flat-to-declining EPS trajectory disqualifies it from compounding portfolios. 7.25% return is below S&P 500 historical average. However, exceptional FCF and low CAPEX are genuine quality markers.

🌐 Sowell: BMY's outcome depends more on POLITICAL events (patent expiry, IRA) than economic competition. Government distortions are the swing factor preventing clear ALCISTA classification.

🔍 Synthesis: Three cautious signals = INVESTIGATE/HOLD. Stock is approximately fairly priced on forward earnings. MONITOR for price weakness that creates margin of safety, while collecting 4.15% dividend yield.

Action Levels

$60.74

Current Price

≤$30.23

Buffett "Right Price"

$43–$77

Graham IV Range

+4.2%

MoS vs Non-GAAP IV

Price Thermometer

Multi-Framework Price Zones

BARGAIN ≤$23BUY ≤$43CURRENT $61FAIR VALUE $77

Bull Case

Lowest forward P/E in big pharma (9.92x) — deeply discounted
9.6% FCF yield — exceptional cash generation
94-year dividend at 4.15% — reliable income
Capital-light operations (CAPEX only 20% of earnings)
ROE 38.7% — high returns on invested capital
Growth Portfolio 55% of revenue with 7 products >$1B

Bear Case

Projected return 7.25% — far below 15% minimum
Revenue forecast to DECLINE 3+ years (-5.27%)
$45B debt from serial acquisitions
Eliquis cliff ACTIVE — EU patent expired May 2026
Not a COMPOUNDER — no organic earnings growth
Temporary patent moat, not permanent competitive advantage

Intrinsic Value Calculation

Buffett Valuation Method

STRONG BUY ≤$15BUY ≤$30HOLD ≤$47OVERVALUED $47+

Step 1: Current Non-GAAP EPS = $6.50 (FY2025)
Step 2: Forward CAGR estimate = 3% (Growth Portfolio minus Eliquis decline)
Step 3: Projected EPS Year 10 = $6.50 × (1.03)^10 = $8.74
Step 4: Future Stock Price = $8.74 × 14 (avg pharma P/E) = $122.30
Step 5: Annualized Return = ($122.30 ÷ $60.74)^(1/10) - 1 = 7.25% — BELOW 15%
Step 6: "Right Price" for 15% return = $122.30 ÷ (1.15)^10 = $30.23
Step 7: Margin of Safety = ($47.15 - $60.74) / $47.15 = -28.8% (OVERVALUED)

"If you aren't willing to own a stock for ten years, don't even think about owning it for ten minutes." — Warren Buffett

Durable Competitive Advantage

Economic Moat Assessment: TEMPORARY

38.7%

ROE

$11.9B

FCF TTM

19.9%

CAPEX/Earn

6.1yr

Debt Payoff

Strong operational characteristics but TEMPORARY patent moat. 71.1% gross margins and 38.7% ROE demonstrate excellent operations. However, Eliquis cliff ($14B revenue at risk by 2031) limits compounding potential. Income stock, not compounder.

Buffett Scorecard

Gross Profit Margin

PASS

71.1%

>40%

ROE

PASS

38.7%

>15%

CAPEX/Earnings

PASS

19.9%

<50%

P/E Forward

PASS

9.92

<40

FCF Yield

PASS

9.6%

>5%

Interest/Op Income

FAIL

11.8%

<10%

Debt Payoff (NI)

FAIL

6.1 years

<4 yr

EPS CAGR (5yr)

FAIL

0.2%

>15%

D/E Adjusted

FAIL

1.15

<0.80

Projected Return

FAIL

7.25%

>15%

Durable Moat

CAUTION

Temporary (patents)

Permanent

Score: 5 PASS / 5 FAIL / 1 CAUTION — Strong operations but insufficient growth for Buffett criteria.

Intrinsic Value — Graham Method

Security Analysis Valuation

BARGAIN ≤$23NORMAL $34MAX INVEST $54CURRENT $61

Step 1: Average Adj GAAP EPS (9yr, excl 2024 write-offs) = $2.71
Step 2: Normal Value = $2.71 × 12.5 = $33.90
Step 3: Bargain Price = $33.90 × 0.667 = $22.60
Step 4: Max Investment Price = $2.71 × 20 = $54.24
Step 5: Current Price = $60.74
Step 6: Non-GAAP Midpoint IV = $5.07 × 12.5 = $63.38
Step 7: MoS vs Non-GAAP = +4.2% (INSUFFICIENT — req 33%)

"The investor's chief problem — and even his worst enemy — is likely to be himself." — Benjamin Graham

Earning Power

$2.71

Adj Avg GAAP EPS

$5.07

Non-GAAP Avg EPS

8.48x

Interest Coverage

94yr

Dividend Record

Graham Scorecard

P/E vs Avg Earnings

FAIL

22.4x (GAAP)

≤ 20x

P/E vs Trailing

PASS

17.01x (Non-GAAP)

≤ 20x

Earnings Stability

FAIL

22.5%

≥ 50%

Interest Coverage

PASS

8.48x

≥ 3x

Current Ratio

FAIL

1.26:1

≥ 2:1

LT Debt Payoff (FCF)

PASS

3.5 years

≤ 4 yr

Book Value vs Price

FAIL

$9.06 vs $60.74

≤ 1x

Dividend Record

PASS

94yr / 18 increases

≥ 10 yr

Revenue Stability

PASS

<10% decline

< 33%

Margin of Safety

FAIL

+4.2%

≥ 33%

Financial Structure

FAIL

D/E 2.31x

Conservative

Score: 5 PASS / 6 FAIL — Does NOT qualify as Graham Investment at current price.

Economic Assessment

Sowell Verdict: NEUTRAL — Transitional Period (Government Distortions Dominate)

Weighted Phases Scorecard

Price Signals

ALCISTA

Fwd P/E 9.92 = market pricing decline; discount may be excessive

Natural Monopoly

NEUTRAL

Artificial monopoly (patents) with defined expiration

Govt Distortions

BAJISTA

IRA price controls + patent cliff = political pricing

Scale & Efficiency

ALCISTA

Capital-light (CAPEX 20%), $1.49M rev/employee

Profit Diagnostics

ALCISTA

ROIC 20.9% far exceeds WACC 4.84%

Systemic Risk

NEUTRAL

Beta 0.24, defensive sector

Scarce Resources

Resource	Status	Trend	Risk
Drug Patents (time-limited)	Critical	Depleting	HIGH
R&D Pipeline Capacity	$13.7B	Rising	MEDIUM
Regulatory Approval Slots	Finite	Constrained	MEDIUM
Specialized Talent	Essential	Rising	MEDIUM

Sowell Conclusion

BMY operates in one of the most GOVERNMENT-DISTORTED sectors. Its fate is determined more by political decisions (patent durations, IRA price negotiations) than by free-market competition. The economic fundamentals are strong but politically-imposed headwinds create uncertainty that prevents a clear directional call. The market's 9.92x forward P/E may be an overcorrection — but the risk is real and politically-driven.